<DOC>
	<DOC>NCT01786473</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of Testogel® 50mg/5g gel administered once daily (QD, morning dosing) compared to placebo administered once daily (QD, morning dosing), for 3 months, in hypogonadal men with testosterone deficiency being confirmed by clinical features and biochemical tests. For men with hypogonadism, treatment aims to restore testosterone levels to normal physiological range.</brief_summary>
	<brief_title>Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male ages 1868 years diagnosed as having testosterone deficiency with clinical symptoms A morning (8:0010:00) serum Total Testosterone concentration of ≤ 300 ng/dL, confirmed by a second measurement of morning serum Total Testosterone concentration ≤ 300 ng/dL (samples to be taken 1 3 weeks apart) Abnormal prostate as evidenced by prostatic symptoms, prostatic masses or induration on rectal examination, or elevated levels of prostate specific antigen (PSA ＞ 4ng/ml) or a maximum urine flow rate of less than 12 ml/sec(of a urine volume greater than 150ml) (and/or an International Prostate Symptom Score IPSS score &gt;19) Hematocrit &gt; 50% Major psychiatric illness Unable to understand the protocol or to give informed consent Use of paroxetine and clomipramine Active alcoholism History of drug abuse within the past five years; Use of drugs that might interfere with the results of the study (e.g., antiandrogen, estrogens or P 450 enzyme inducers, barbiturates); BMI &lt; 18 or &gt; 30 according to Chinese BMI references; Generalized skin disease that may affect absorption of T (e.g., psoriasis) or a known skin intolerance to alcohol; Prolactin &gt; 40 mcg/L; Untreated severe obstructive sleep apnea;. Uncontrolled or poorly controlled heart failure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>